Concepedia

Niklas Uhlenbrock

NU

Statistics

Publications

8

Citations

475

H-Index

8

Active since

2015

Affiliations

TU Dortmund University(Current)

German Cancer Research Center

Heidelberg University

Lead Discovery Center (Germany)

Deutsches Konsortium für Translationale Krebsforschung

Niklas Uhlenbrock is an author at TU Dortmund University specializing in pharmacology, ligand binding, and medicinal chemistry.

ORCID

Publications per year

2015–2023

8

Publications

8

Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach

Julian Engel, André Richters, Matthäus Getlik et al. · Journal of Medicinal Chemistry · 2015 · 112 citations · Full text

, , +16

Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination with Trametinib in <i>KRAS</i>-Mutant Pancreatic and Colorectal Cancer

Jörn Weisner, Ina Landel, Christoph Reintjes et al. · Cancer Research · 2019 · 91 citations

, , +17

Covalent‐Allosteric Inhibitors to Achieve Akt Isoform‐Selectivity

Lena Quambusch, Ina Landel, Laura Depta et al. · Angewandte Chemie International Edition · 2019 · 71 citations · Full text

, , +17

Structural and chemical insights into the covalent-allosteric inhibition of the protein kinase Akt

Niklas Uhlenbrock, Steven P. Smith, Jörn Weisner et al. · Chemical Science · 2019 · 70 citations · Full text

, , +17

Cellular model system to dissect the isoform-selectivity of Akt inhibitors

Lena Quambusch, Laura Depta, Ina Landel et al. · Nature Communications · 2021 · 54 citations · Full text

, , +16

1–5 of 8